Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2020 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and 2019 Financial Results
Accelerated Approval Pathway Defined for Mirvetuximab Soravtansine in Ovarian Cancer; Pivotal SORAYA Trial Expected to Enroll First Patient in Q1 2020 Phase 3 Confirmatory MIRASOL Trial for Mirvetuximab Enrolling Patients Updated IMGN632 AML and BPDCN Monotherapy Data Presented at ASH $97.6 Million
View HTML
Toggle Summary ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
View HTML
Toggle Summary ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 3, 2020-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 31, 2020 the compensation committee of the Company’s board of directors granted a
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its 2019 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 30, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 27, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 24,523,750 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 22, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 21,325,000 shares of its common stock at a price of
View HTML
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 22, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2020-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 38 th Annual J.P.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 31, 2019-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 23, 2019 the compensation committee of the Company’s Board of Directors granted a
View HTML